Samsung Medical Center
π°π·South Korea
- Country
- π°π·South Korea
- Ownership
- Subsidiary
- Established
- 1994-01-01
- Employees
- 501
- Market Cap
- -
Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2019-12-30
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 21
- Registration Number
- NCT02451956
- Locations
- π°π·
Samsung Medical Center, Seoul, Seoul, Korea, Republic Of, Korea, Republic of
Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors
- First Posted Date
- 2015-05-21
- Last Posted Date
- 2017-03-13
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 1
- Registration Number
- NCT02450149
- Locations
- π°π·
Samsung Medical Center, Seoul, seoul, korea, Republic of, Korea, Republic of
Lateral Rectus Muscle and Anterior Segment Optical Coherence Tomography (AS-OCT) in Two Recession Surgeries
- Conditions
- Intermittent Exotropia
- Interventions
- Procedure: lateral rectus recession (bilateral)
- First Posted Date
- 2015-05-21
- Last Posted Date
- 2015-05-21
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 60
- Registration Number
- NCT02450162
Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors
- First Posted Date
- 2015-05-21
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 2
- Registration Number
- NCT02450136
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors
- First Posted Date
- 2015-05-21
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 1
- Registration Number
- NCT02450123
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment
- First Posted Date
- 2015-05-20
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 16
- Registration Number
- NCT02449551
- Locations
- π°π·
Samsung Medical center, Seoul, Korea, Republic of
Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line Chemotherapy
Phase 2
Terminated
- Conditions
- Advanced Gastric Adenocarcinoma
- Interventions
- First Posted Date
- 2015-05-20
- Last Posted Date
- 2019-05-20
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 27
- Registration Number
- NCT02449655
- Locations
- π°π·
Samsung Medical center, Seoul, Korea, Republic of
The Pilot Study Evaluate the Safety and Efficacy of Sirolimus in Patients With PIK3CA Mutation and/or PIK3CA Amplification Refractory Solid Tumors
- First Posted Date
- 2015-05-20
- Last Posted Date
- 2018-01-17
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 5
- Registration Number
- NCT02449564
- Locations
- π°π·
Samsung Medical center, Seoul, Korea, Republic of
Study to Evaluate the Safety and Efficacy of Everolimus, in Subjects With PIK3CA Amplification, PTEN Loss and PIK3CA Mutation Refractory Solid Tumors
- First Posted Date
- 2015-05-20
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT02449538
- Locations
- π°π·
Samsung Medical center, Seoul, Korea, Republic of
Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy
- First Posted Date
- 2015-05-19
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 26
- Registration Number
- NCT02448329
- Locations
- π°π·
Samsung Medical center, Seoul, Korea, Republic of
Β© Copyright 2025. All Rights Reserved by MedPath